Genómica traslacional y terapias dirigidas en tumores sólidos
Publicaciones destacadas
-
A prognostic model based on PAM50 and clinical variables (PAM50MET) for metastatic hormone-receptor-positive HER2-negative breast cancer
Prat A; Tsai YH; Pascual T; Paré L; Adamo B;(...)Brase JC; Rodrik-Outmezguine V; Johnston S; Ciruelos E; Parker JS .Referencia:Clinical Cancer Research 2020.
-
Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial
Ciruelos E; Villagrasa P; Pascual T; Oliveira M; Pernas S;(...)Galván P; Canes J; Nuciforo P; Gonzalez X; Prat A .Referencia:Clinical Cancer Research 2020.
-
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis
Schettini F; Pascual T; Conte B; Chic N; Brasó-Maristany F;(...)Osborne CK; Pernas S; Perou CM; Carey LA; Prat A.Referencia:Cancer Treatment Reviews 2020.
-
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
Brasó-Maristany F.; Griguolo G.; Pascual T.; Paré L.; Nuciforo P.;(...)Gomis R.R.; Villagrasa P.; Cortés J.; Ciruelos E.; Prat A..Referencia:Nature Communications 2020.
-
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial
Prat A; Saura C; Pascual T; Hernando C; Muñoz M;(...)López R; Céliz P; Ciruelos E; Villagrasa P; Gavilá J .Referencia:Lancet Oncology 2020.
-
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
Prat A; Pascual T; De Angelis C; Gutierrez C; Llombart-Cussac A;(...)Conte P; Schiff R; Guarneri V; Osborne CK; Rimawi MF.Referencia:Journal Of The National Cancer Institute 2020.
-
Immune-related adverse events of checkpoint inhibitors
Ramos-Casals M; Brahmer JR; Callahan MK; Flores-Chávez A; Keegan N;Khamashta MA; Lambotte O; Mariette X; Prat A; Suárez-Almazor ME .Referencia:Nature Reviews Disease Primers 2020.
-
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer
Veeraraghavan J; De Angelis C; Mao R; Wang T; Herrera S;(...)Reis-Filho JS; Gutierrez C; Osborne CK; Rimawi MF; Schiff R .Referencia:Annals Of Oncology 2019.
-
Patients’ Experience of Living with Cancer-associated thrombosis in Spain (PELICANOS)
Font C; Nelson A; Garcia-Fernandez T; Prout H; Gee P;Noble S.Referencia:Supportive Care In Cancer 2018.
-
Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer
Martín A; Ortega I; Font C; Pachón V; Castellón V;(...)Rupérez A; Souto J; Martín M; Salas E; Soria J.Referencia:British Journal Of Cancer 2018.